TrialDiabetes, obesity & metabolism2023

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.

Ryosuke Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.